BioPharmSignal logoBioPharmSignal

Biotech News

Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference

Structure Therapeutics (GPCR)Structure TherapeuticsConference / presentation

SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced that management will

Related news

ACRSAclaris Therapeutics2026-09-03 12:00 EST

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

GPCRStructure Therapeutics2026-09-03 11:30 EST

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

XFORX4 Pharmaceuticals2026-09-09 11:00 EST

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

ZURAZura Bio2026-08-31 20:30 EST

Zura Bio to Participate in the Cantor Global Healthcare Conference

SABSSAB Biotherapeutics2026-10-14 12:30 EST

SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

GPCRStructure Therapeutics2026-10-19 20:14 EST

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026

VERAVera Therapeutics2026-10-02 13:24 EST

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

KNSAKiniksa2026-09-04 20:01 EST

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

CMMBChemomab Therapeutics2026-08-31 12:00 EST

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

HCMHUTCHMED2026-10-27 00:00 EST

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

View all latest news

Structure Therapeutics

Structure-Based Metabolic Drug Discovery Structure Therapeutics develops oral small molecules against validated metabolic targets using structure-based drug design. Its franchise is intended to offer oral alternatives to injectable peptide therapies. Aleniglipron Aleniglipron is an oral GLP-1 receptor agonist in development for obesity...

Recent company news

GPCRStructure Therapeutics2026-11-04 12:30 EST

Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference

GPCRStructure Therapeutics2026-10-19 20:14 EST

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026

GPCRStructure Therapeutics2026-09-08 12:00 EST

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

GPCRStructure Therapeutics2026-09-03 11:30 EST

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Stock data

Close
19.08 USD
Market cap
2.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States